Sign in

LEGN on Nasdaq

Legend Biotech

Legend Biotech is a Biotech company based in Moling Subdistrict, founded in 2014.1 Its shares trade on Nasdaq under the symbol LEGN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$296.8MNet income, fiscal 20254
Nov 17, 2014Founded1

Compare with Amicus Therapeutics, TG Therapeutics or Axsome Therapeutics, or pick any stock.

  • TickerLEGN on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersJiangning District1
  • Websitewww.legendbiotech.com
  • Incorporated inCayman Islands5
  • Business address2101 Cottontail Lane, Somerset, Nj 088735
  • Filer categoryLarge accelerated filer5
  • Legal formCorporation3
  • LEI254900EIUFZTW136H8593
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressPO Box 10240, KY1-1002 George Town, Cayman Islands3
  • Registered withGeneral Registry, HL-3001593

See how the biggest companies compare on our leaderboards

Our principal executive offices are located at 2101 Cottontail Lane, Somerset, New Jersey 08873, and our phone number is (737) 317-5050. The registered office address of the Company is Harneys Fiduciary (Cayman) Limited, 4 th Floor, Harbour Place, 103 South Church Street, PO Box 10240, Grand Cayman KY1-1002, Cayman Islands. Our agent for service of process in the United States is Ying Huang, Ph.D., Chief Executive Officer, Legend Biotech Corporation, 2101 Cottontail Lane, Somerset, New Jersey 08873.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-49.3%Operating margin4
-28.2%Net margin4
120.0%Revenue growth, 20247
-17.0%Return on equity4
0.29×Debt to equity4
-$158.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue32¢$216.4M
  • Research and development62¢$413.5M
  • Interest3¢$21.6M
  • Income tax3¢$18.9M

Out of $627.2M in revenue.74 The company lost money this year.

Financial statements

Revenue8910117$627.2M in 2024+1177% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $49.1M$49.1M20182019: $60.0M$60.0M2019+22%2020: $75.0M$75.0M2020+25%2021: $68.8M$68.8M2021−8%2022: $117.0M$117.0M2022+70%2023: $285.1M$285.1M2023+144%2024: $627.2M$627.2M2024+120%
Operating income4-$309.5M in 2024−41% since 2023
-$600.0M-$400.0M-$200.0M02023: -$528.1M-$528.1M20232024: -$309.5M-$309.5M2024−41%
Net income89101174-$177.0M in 2024+6258% since 2018
-$600.0M-$400.0M-$200.0M02018: -$2.8M-$2.8M20182019: -$101.6M-$101.6M2019+3549%2020: -$266.4M-$266.4M2020+162%2021: -$403.6M-$403.6M2021+52%2022: -$446.3M-$446.3M2022+11%2023: -$518.3M-$518.3M2023+16%2024: -$177.0M-$177.0M2024−66%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
License and other revenue$84.1M$144.7M$35.3M
Collaboration revenue$944.8M$482.6M$249.8M
Total revenue$1.0B$627.3M$285.1M
Cost of collaboration revenue-$397.1M-$216.4M-$144.2M
Cost of license and other revenue-$11.0M-$18.2M$0
Research and development expenses-$414.7M-$413.5M-$382.2M
Administrative expenses-$135.8M-$136.8M-$106.8M
Selling and distribution expenses-$205.8M-$147.5M-$94.2M
Other operating expense-$1.0M-$4.4M-$85.8M
Operating loss-$136.5M-$309.5M-$528.1M
Finance costs-$21.4M-$21.6M-$21.8M
Finance income$40.1M$61.2M$54.5M
Other (expense)/ income, net-$164.8M$111.8M-$24.8M
Loss before tax-$282.6M-$158.1M-$520.2M
Income tax (expense)/benefit-$14.2M-$18.9M$1.9M
Net loss-$296.8M-$177.0M-$518.3M
Basic (in dollars per share)-$0.81-$0.48-$1.47
Diluted (in dollars per share)-$0.81-$0.48-$1.47
Exchange differences on translation of foreign operations$190.4M-$112.5M$29.6M
Other comprehensive income/(loss), net of tax$190.4M-$112.5M$29.6M
TOTAL COMPREHENSIVE LOSS-$106.4M-$289.5M-$488.7M

Compare Legend Biotech with another company

Corporate structure

Legend Biotech is part of a group headed by Genscript Biotech Corporation. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Legend Biotech

  • Genscript Biotech Corporation George Town, Cayman Islands
    • Legend Biotech Somerset, New Jersey, United States
    • Probio Technology Limited Subsidiary · George Town, Cayman Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Legend Biotech reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$116.3M4 Dec 31, 2025$99.3M4 Dec 31, 2024+17.1%
Operating-lease assets (leased space)$285.2M4 Dec 31, 2025$101.9M4 Dec 31, 2024+179.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$901.9M4 Dec 31, 2025$286.7M4 Dec 31, 2024+214.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.9M4 Dec 31, 2025$2.2M4 Dec 31, 2024−13.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$32.0M4 Dec 31, 2025$23.9M4 Dec 31, 2024+33.9%

Leadership

Who has led Legend Biotech, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alan Bash2026
  2. Ingrid Zhang2026–now
201520202025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerLori Macomber named Apr 28, 202323
  • Executive Officer, DirectorYing Huang, Ph.D. named Apr 28, 202323
  • DirectorCorazon D. Sanders, Ph.D. named Apr 28, 202323
  • DirectorDarren Xiaohui Ji, M.D., Ph.D. named Apr 28, 202323
  • DirectorFangliang Zhang, Ph.D. named Apr 28, 202323
  • DirectorLi Zhu, Ph.D. named Apr 28, 202323
  • DirectorPatrick Wai Man Casey, Ph.D. named Apr 28, 202323
  • DirectorPhilip Wai Man Yau, CPA named Apr 28, 202323

Subsidiaries and ownership

Parent company (GLEIF)

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

  1. Sep 16, 2026New chief executive Ingrid Zhang becomes CEO13
  2. Aug 3, 2026New chief executive Alan Bash becomes CEO12
  3. May 27, 2015Parent Directly consolidated by Genscript Biotech Corporation3
  4. Nov 17, 2014Founded Founded1

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.11) a share, on Nov 12, 2025.24

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

310 filings to the SEC since October 2021: 6 annual reports, 28 insider forms, 23 large holders, 1 private raises, 252 other. The latest 20:

  1. Oct 15, 20266-K EDGAR
  2. Oct 13, 20266-K EDGAR
  3. Oct 7, 2026S-8 EDGAR
  4. Oct 1, 20264 EDGAR
  5. Sep 29, 2026144 EDGAR
  6. Sep 28, 20264 EDGAR
  7. Sep 28, 20264 EDGAR
  8. Sep 28, 20264 EDGAR
  9. Sep 28, 20264 EDGAR
  10. Sep 28, 20264 EDGAR
  11. Sep 28, 20264 EDGAR
  12. Sep 25, 20266-K EDGAR
  13. Sep 24, 20266-K EDGAR
  14. Sep 23, 20264 EDGAR
  15. Sep 22, 2026144 EDGAR
  16. Sep 22, 2026144 EDGAR
  17. Sep 16, 20264 EDGAR
  18. Sep 16, 20263 EDGAR
  19. Sep 15, 20266-K EDGAR
  20. Sep 14, 20266-K EDGAR

The 310 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 21, 2026Santos Carlos EChief Financial OfficerSale5,430$9.14$49.6KForm 4
Jun 30, 2026Casey Patrick JohnDirectorSale6,000$14.80$88.8KForm 4
Jun 25, 2026Huang YingChief Executive OfficerSale5,566$14.78$82.3KForm 4
Mar 25, 2026Huang YingChief Executive OfficerSale9,936$8.77$87.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$200.0M 2023–2023
Money received by yearMoney received by year, 2023–2023: $200.0M in all. Private raises (Form D) $200.0M.$0$100M$200M$300M2023 · Private raises (Form D): $200.0M2023
Figures by year
YearPrivate raises (Form D)Total
2023$200.0M$200.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Apr 19, 2023Raised $200 million in a private offering of equity23 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC29,093,899$840.2M0.0%+3,397,159
Deerfield Management Company, L.P.8,137,638$235.0M2.9%+450,000
Montanova Capital, LLC7,070,000$204.2M4.3%−511,029
Hhlr Advisors, Ltd.5,984,550$172.8M20.8%No change
BlackRock, Inc.4,726,534$136.5M0.0%+41,991
Westfield Capital Management Co LP4,430,063$127.9M0.4%−1,333,412
Assenagon Asset Management S.A.3,830,112$110.6M0.1%New
Goldman Sachs Group Inc3,662,315$105.8M0.0%+2,198,203
Point72 Asset Management, L.P.3,076,124$88.8M0.1%−809,893
Kynam Capital Management, LP3,001,205$86.7M4.8%+1,424,910
Artisan Partners Limited Partnership1,559,441$45.0M0.1%−695,047
State Street Corp1,498,704$43.3M0.0%+332
Capital International Investors1,420,654$41.0M0.0%+772,804
Morgan Stanley1,394,531$40.3M0.0%+791,284
Soleus Capital Management, L.P.1,205,000$34.8M1.2%New
Davern Capital Partners, LP1,191,522$34.4M5.9%−123,226
Driehaus Capital Management LLC1,158,808$33.5M0.2%New
Renaissance Technologies LLC1,000,200$28.9M0.0%+478,400
Ghisallo Capital Management LLC1,000,000$28.9M0.7%New
Matthews International Capital Management LLC917,266$26.5M9.1%−8,654
Johnson & Johnson814,586$23.5M2.9%No change
IvyRock Asset Management (HK) Ltd801,000$23.1M13.1%−3,000
EcoR1 Capital, LLC800,000$23.1M1.1%New
Jpmorgan Chase & Co766,364$22.5M0.0%+478,261
Squarepoint Ops LLC769,252$22.2M0.0%+289,772

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Legend Biotech is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLegend Biotech Corp2
  • CIK0001801198
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company6
  • Incorporated inCayman Islands6
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address2101 Cottontail Lane, Somerset, NJ 088732
  • Phone732-850-55982
  • Shares outstanding369,886,369 shares as of Dec 31, 20256
  • AuditorErnst & Young LLP, Iselin, New Jersey PCAOB ID 42; it also attests to the company’s internal control over financial reporting6
  • On EDGAR sinceMar 9, 20202
  • Filings384 in all: 6-K (194), 144 (70), 3 (14), 4 (14), SC 13G/A (13), UPLOAD (11), CORRESP (9), 424B5 (7)2
    All 33 form types

    SC 13G (7), SCHEDULE 13G/A (7), 20-F (6), EFFECT (3), F-3ASR (3), S-8 (3), 144/A (2), D (2), DRS/A (2), DRSLTR (2), 20-F/A (1), 424B3 (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1/A (1), F-3 (1), F-6 (1), F-6/A (1), F-6EF (1), FWP (1), S-8 POS (1)

  • Latest filingsAnnual report (20-F) Mar 10, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares, each representing two ordinary shares, par value $0.0001 per shareLEGNNasdaq Global Select Market

From the cover page of the 20-F filed Mar 10, 2026 (Section 12(b) of the Exchange Act).6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31